AKT Health Inc.

Are you finding it challenging to manage the vast amounts of PK/PD data required for today’s complex clinical trials? Searching, visualizing, and analyzing this data—while remaining compliant with regulatory submissions—can be overwhelming. That’s where Certara’s Integral data and model repository comes in. Our secure, cloud-based platform is 21 CFR Part 11 compliant, ensuring that all your PK/PD models, study data, and results are organized in a single validated environment. With Integral, you can streamline your workflows, enhance compliance, and make better-informed drug development decisions all while staying 21 CFR Part 11 compliant. Curious to learn more? Check out our latest webinar to see how Certara’s Integral can transform your PK/PD processes: https://lnkd.in/eu7pbpUs If you’re looking to optimize your PK/PD processes and stay ahead in the regulatory landscape, feel free to reach out to me. Let’s discuss how Certara can support your success! AKT Health Inc. Certara #DrugDevelopment #PKPD #ClinicalTrials #RegulatoryCompliance #Pharmaceuticals #Certara #Integral

At AKT Health Inc. Boston, US we do a monthly series on Decentralized Clinical trials. We are asked often the purpose of building this community. I had an opportunity this month at the DCT series VIII ,thanks to our dear friends David A. Hall MHA, MA, MIS/IT, PMP and Fion Liao, to explain why we do what we do. You'd like to know too? Listen on to the video below. #DCTs #Boston #RWE

🚀 Webinar Recap: AI's Impact on Healthcare 🚀 This insightful webinar featured a keynote by Dr. Ang Yee Gary and a dynamic panel discussion with our Doctor Innovators, Dr. Aguiar, Dr. Olagunju, and Dr. Alaran, diving into AI’s transformative role in healthcare. ✨ Keynote Highlights: Dr. Gary on “Large Language Models in Patient Education” Dr. Gary explored the application of AI, including GPT-powered systems, in simulating human conversations, summarizing health information, and automating essential tasks like scheduling. He shared exciting projects, such as AI-driven lung tests and voice analysis for detecting conditions like depression. 🎯 Insightful Dialogues Highlights: 💡 Conversational AI: Advancing patient inquiries, scheduling, and documentation with technologies like ambient AI. 💡 Mental Health Detection: Innovating speech analysis to detect conditions like anxiety, focusing on large-scale validation. 💡 AI in Low-Resource Settings: Emphasizing local language integration and SMS-based solutions for low-bandwidth areas. 🔍 Q&A Insights: AI's evolving role in categorizing patient feedback and automating repetitive tasks was discussed, with a focus on data security and the critical role of human oversight. 🔔 Conclusion: This session emphasized the responsible deployment of AI in healthcare. Save the date for our next webinar on November 16, focusing on AI innovation with Sanofi. 👉 Watch the recording to explore AI’s evolving role in healthcare and gain valuable insights! https://lnkd.in/exmbW_DN

Work commitments may have kept me from attending the MarketsandMarkets™ event in person, but thanks to the benefits of virtual connections, I gained valuable insights from the event. Aditya Tallapragada shared one of the key highlights that resonated with me during his discussion on the future of #decentralized #clinicaltrials and #digitalhealth technologies. His talk was truly eye-opening. He emphasized how #DCTs are reshaping #clinicalresearch by placing #patients at the center and leveraging #technologies like #wearables and #remotemonitoring to enhance participation and compliance. The integration of #AI and #IoT is accelerating #realtime #data collection, allowing for #predictiveanalytics and early interventions to improve #patientoutcomes. #Blockchain also plays a crucial role by ensuring #datasecurity and transparency in sharing sensitive patient information. Aditya highlighted the #regulatory challenges of validating #AI and new technologies, as well as how #cloudcomputing and #bigdata are revolutionizing evidence generation, speeding up #trials, and reducing the time-to-market for new therapies. Conversations like these are vital for driving our industry forward, underscoring the significance of embracing cutting-edge technologies to enhance #clinical #outcomes. As we look to the future, I am excited about the potential of these innovations to transform #healthcare and improve #patientexperiences. I look forward to exploring the practical applications of these insights in our ongoing work in clinical research. #DCTs #ai #blockchain #RPM AKT Health Inc. #healthcaretransformation #innovation #CRO #patientoutcome

It was a fabulous honor to host this 7th annual RWE real world evidence and life science analytics conference at Boston. Logan airport Hilton together with Aditya Tallapragada and Rashmi Gurnani AKT Health Inc.

🌟 AstraZeneca's New AI Tool 'MILTON' Could Revolutionize Pharma R&D—Here's What It Means for the Industry! 🌟 AstraZeneca's AI tool MILTON—which stands for "Machine Learning with Phenotype Associations"—is pushing the boundaries of disease prediction. Leveraging health data from the UK Biobank, MILTON can predict over 1,000 diseases before diagnosis using 67 biomarkers regularly collected in clinical practice. This innovation represents a significant leap forward for predictive medicine and genetic discovery. So, what does this mean for other pharma companies? 💡 AI for Early Detection: With MILTON demonstrating high accuracy in predicting diseases, pharma companies now have a powerful example of how AI can accelerate drug discovery and personalize treatments. 💡 Precision and Personalization: AI tools like MILTON will enable pharma companies to develop more targeted therapies, improving treatment efficacy while reducing trial-and-error approaches. 💡 Data-Driven Innovation: By correcting misclassifications common in traditional studies, MILTON shows the way forward in harnessing large biobank datasets for groundbreaking research and early detection. At AKT Health Inc., we help life science companies embrace AI and advanced analytics to enhance R&D, optimize clinical trials, and scale predictive tools like MILTON for real-world use. Our expertise in AI-powered solutions can help pharma companies replicate success, ensuring faster timelines and better patient outcomes. 🔬 Ready to integrate AI like MILTON into your strategy? Let AKT Health guide your innovation journey. #AIinHealthcare #PharmaInnovation #PrecisionMedicine #DigitalHealth #AKTHealth #ClinicalTrials #AstraZeneca

At AKT Health Inc., we are excited to collaborate with pharmaceutical innovators looking for cutting-edge solutions in data analytics and AI-driven insights to optimize your drug development process and regulatory strategy. 🤔 Why partner with us? We provide comprehensive analytics services, including: - Clinical Data Management - Real-World Evidence Generation - AI-Powered Analytics Our solutions enable faster, more informed decision-making across clinical trials, regulatory submissions, and market access strategies. With a dedicated team and a proven track record, we deliver timely and impactful results for every project. #BusinessDevelopment #NewCollaboration #HealthcareAnalytics #PharmaceuticalBusinessDevelopment #ClinicalDataManagement #AIInPharma

Streamline your PK/PD analysis with Certara's Phoenix WinNonlin! In today's fast-paced drug development environment, precision and efficiency are crucial. Phoenix WinNonlin offers advanced PK/PD modeling, user-friendly workflows, and comprehensive data visualization for robust analysis. This game-changer ensures full regulatory compliance and proven results in bioequivalence and therapeutic response studies. Who should use it? Clinical pharmacologists to formulation scientists benefit from gaining critical insights for data-driven decision-making. Empower your research with Phoenix WinNonlin to simplify complex data analysis, reduce time to results, and enhance drug safety and efficacy evaluations. With Certara's Phoenix WinNonlin, your team can confidently accelerate the path from discovery to market. Certara AKT Health Inc. #PKPD #PharmaInnovation #Certara #PhoenixWinNonlin #DrugDevelopment #Pharmacokinetics #Pharmacodynamics #ClinicalTrials

Following the success of the #DCTs Series in #Boston, we're excited to bring the #DCTs Quarterly Series to #Tokyo!Join us on November 15, as we dive into the latest #innovations #transforming the #healthcare industry   What to Expect: ✅ Insightful keynote presentations from industry leaders. ✅Engaging panel discussions on Empowering Innovation: How DCTs are Revolutionizing Pharma in Japan ✅Networking opportunities Our DCT team David A. Hall MHA, MA, MIS/IT, PMP , Fion Liao, Hema Dubey, 武田綾香, Kripa Subba—all working together to bring the best insights and #innovations to the forefront of the #DCTs Series 2024. https://lnkd.in/d7P8tsTz Register now: 🗒️ DCTs Quarterly Series 2024 Tokyo: https://lnkd.in/dPKxrE2M 🗒️DCTs Monthly Series2024 Boston: https://lnkd.in/dMvmtXug Be part of this #transformative event—where #healthcare meets #innovation

This study sheds light on the multifaceted impact of various factors on brain aging in underserved populations. Your in-depth analysis opens up important discussions on health disparities and the need for more inclusive research.